TN2010000199A1 - Improved nogo-a binding molecules and pharmaceutical use thereof - Google Patents

Improved nogo-a binding molecules and pharmaceutical use thereof

Info

Publication number: TN2010000199A1
Authority: TN; Tunisia
Prior art keywords: binding molecule; nogo; improved; binding molecules; pharmaceutical use
Prior art date: 2007-11-02

Application number

TN2010000199A

Other languages

English (en)

Inventor

Carmen Barske

Stefan Frentzel

Anis Khurso Mir

Martin E Schwab

Alessandra Vitaliti

Original Assignee

Novartis Ag

Univ Zuerich

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-02

Filing date

2010-04-30

Publication date

2011-11-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000199(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-30 Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag

2011-11-11 Publication of TN2010000199A1 publication Critical patent/TN2010000199A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

TN2010000199A 2007-11-02 2010-04-30 Improved nogo-a binding molecules and pharmaceutical use thereof TN2010000199A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07119847		2007-11-02
PCT/EP2008/064501 WO2009056509A1 (fr)	2007-11-02	2008-10-27	Molécules améliorées de liaison à nogo-a et utilisation pharmaceutique de celles-ci

Publications (1)

Publication Number	Publication Date
TN2010000199A1 true TN2010000199A1 (en)	2011-11-11

Family

ID=39156235

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000199A TN2010000199A1 (en)	2007-11-02	2010-04-30	Improved nogo-a binding molecules and pharmaceutical use thereof

Country Status (30)

Country	Link
US (2)	US8163285B2 (fr)
EP (1)	EP2207808B1 (fr)
JP (1)	JP5698534B2 (fr)
KR (1)	KR101574814B1 (fr)
CN (1)	CN101910200B (fr)
AR (1)	AR072934A1 (fr)
AU (1)	AU2008317724B2 (fr)
BR (1)	BRPI0818928B1 (fr)
CA (1)	CA2704357C (fr)
CL (1)	CL2008003240A1 (fr)
CO (1)	CO6270357A2 (fr)
CY (1)	CY1114345T1 (fr)
DK (1)	DK2207808T3 (fr)
ES (1)	ES2425768T3 (fr)
HR (1)	HRP20130699T1 (fr)
IL (2)	IL205357A (fr)
JO (1)	JO2876B1 (fr)
MA (1)	MA31805B1 (fr)
MX (1)	MX2010004831A (fr)
MY (1)	MY149546A (fr)
NZ (1)	NZ584911A (fr)
PE (1)	PE20090981A1 (fr)
PL (1)	PL2207808T3 (fr)
PT (1)	PT2207808E (fr)
RU (1)	RU2513697C2 (fr)
SI (1)	SI2207808T1 (fr)
TN (1)	TN2010000199A1 (fr)
TW (1)	TWI429656B (fr)
WO (1)	WO2009056509A1 (fr)
ZA (1)	ZA201002799B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8828390B2 (en)	2010-07-09	2014-09-09	Universitat Zurich	Uses of NOGO-A inhibitors and related methods
EP2870177A1 (fr)	2012-07-05	2015-05-13	Glaxo Group Limited	Régime posologique optimal d'un anticorps anti-nogo-a dans le traitement de la sclérose latérale amyotrophique
HRP20220436T1 (hr) *	2015-11-03	2022-05-27	Janssen Biotech, Inc.	Protutijela koja se specifično vežu na pd-1 i njihove uporabe
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20220087516A (ko)	2019-10-24	2022-06-24	노바고 테라퓨틱스 아게	신규 항-Nogo-A 항체
CN119768424A (zh) *	2022-08-22	2025-04-04	舒泰神（北京）生物制药股份有限公司	特异性识别Nogo-A的抗体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308573D0 (en)	1983-03-29	1983-05-05	British Nuclear Fuels Ltd	Filament impregnating/coating
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DE3785186T2 (de)	1986-09-02	1993-07-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
AU642404B2 (en)	1989-02-13	1993-10-21	Schering Aktiengesellschaft Berlin Und Bergkamen	Novel thrombolytic
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
CA2350395C (fr) *	1998-11-06	2014-07-08	Martin E. Schwab	Sequences nucleotidiques et proteiques de gene nogo et procedes reposant sur ces sequences
CN1234730C (zh) *	2001-12-30	2006-01-04	上海中科伍佰豪生物工程有限公司	鼠抗氯霉素单克隆抗体及其用途
US7531178B2 (en)	2002-06-07	2009-05-12	Trigen Gmbh	Immunoadhesin comprising a glycoprotein VI domain
GB0228832D0 (en)	2002-12-10	2003-01-15	Novartis Ag	Organic compound
DK1639011T3 (da)	2003-06-30	2009-02-16	Domantis Ltd	Pegylerede enkelt-domæne antistoffer (dAb)
GB0321997D0 (en)	2003-09-19	2003-10-22	Novartis Ag	Organic compound
EP1706426A2 (fr) *	2003-12-22	2006-10-04	Glaxo Group Limited	Anticorps nogoa pour le traitement de la maladie d'alzheimer
GB0329684D0 (en) *	2003-12-22	2004-01-28	Glaxo Group Ltd	Method
EP1801208A4 (fr)	2004-09-06	2009-04-01	Kirin Pharma Kk	Anticorps anti-a33
PL1899377T3 (pl) *	2005-07-05	2013-01-31	Glaxo Group Ltd	Humanizowane przeciwciała specyficzne dla nogo-a i ich zastosowania farmaceutyczne
GB0525662D0 (en) *	2005-12-16	2006-01-25	Glaxo Group Ltd	Immunoglobulins
KR20090039787A (ko)	2006-07-18	2009-04-22	센토코 인코포레이티드	인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
PE20091388A1 (es)	2007-11-02	2009-09-24	Novartis Ag	Moleculas y metodos para modular el componente de complemento
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
KR101039751B1 (ko)	2008-10-16	2011-06-09	한국생명공학연구원	Ｔｍｐｒｓｓ４―특이적인 인간항체

2008
- 2008-10-27 PT PT88438494T patent/PT2207808E/pt unknown
- 2008-10-27 US US12/740,777 patent/US8163285B2/en active Active
- 2008-10-27 MY MYPI2010001822A patent/MY149546A/en unknown
- 2008-10-27 DK DK08843849.4T patent/DK2207808T3/da active
- 2008-10-27 ES ES08843849T patent/ES2425768T3/es active Active
- 2008-10-27 HR HRP20130699AT patent/HRP20130699T1/hr unknown
- 2008-10-27 NZ NZ584911A patent/NZ584911A/en not_active IP Right Cessation
- 2008-10-27 PL PL08843849T patent/PL2207808T3/pl unknown
- 2008-10-27 JP JP2010531504A patent/JP5698534B2/ja active Active
- 2008-10-27 SI SI200831001T patent/SI2207808T1/sl unknown
- 2008-10-27 EP EP08843849.4A patent/EP2207808B1/fr active Active
- 2008-10-27 RU RU2010122044/10A patent/RU2513697C2/ru active
- 2008-10-27 KR KR1020107012080A patent/KR101574814B1/ko not_active Expired - Fee Related
- 2008-10-27 AU AU2008317724A patent/AU2008317724B2/en not_active Ceased
- 2008-10-27 CN CN2008801237017A patent/CN101910200B/zh not_active Expired - Fee Related
- 2008-10-27 WO PCT/EP2008/064501 patent/WO2009056509A1/fr not_active Ceased
- 2008-10-27 MX MX2010004831A patent/MX2010004831A/es active IP Right Grant
- 2008-10-27 CA CA2704357A patent/CA2704357C/fr not_active Expired - Fee Related
- 2008-10-27 BR BRPI0818928-5A patent/BRPI0818928B1/pt not_active IP Right Cessation
- 2008-10-30 PE PE2008001859A patent/PE20090981A1/es active IP Right Grant
- 2008-10-30 JO JO2008490A patent/JO2876B1/en active
- 2008-10-30 CL CL2008003240A patent/CL2008003240A1/es unknown
- 2008-10-31 TW TW097142276A patent/TWI429656B/zh not_active IP Right Cessation
2009
- 2009-08-10 AR ARP090103071A patent/AR072934A1/es unknown
2010
- 2010-04-21 ZA ZA2010/02799A patent/ZA201002799B/en unknown
- 2010-04-26 IL IL205357A patent/IL205357A/en active IP Right Grant
- 2010-04-30 TN TN2010000199A patent/TN2010000199A1/fr unknown
- 2010-04-30 CO CO10051504A patent/CO6270357A2/es active IP Right Grant
- 2010-04-30 MA MA32813A patent/MA31805B1/fr unknown
2012
- 2012-03-16 US US13/422,642 patent/US8758754B2/en active Active
- 2012-08-30 IL IL221723A patent/IL221723A/en active IP Right Grant
2013
- 2013-08-08 CY CY20131100676T patent/CY1114345T1/el unknown

Also Published As

Publication number	Publication date
HRP20130699T1 (hr)	2013-11-22
IL221723A0 (en)	2012-10-31
PE20090981A1 (es)	2009-08-13
KR20100100848A (ko)	2010-09-15
JP5698534B2 (ja)	2015-04-08
EP2207808A1 (fr)	2010-07-21
BRPI0818928A2 (pt)	2017-05-16
PT2207808E (pt)	2013-08-26
CA2704357C (fr)	2016-06-21
IL205357A (en)	2014-08-31
JP2011502476A (ja)	2011-01-27
IL205357A0 (en)	2010-12-30
MA31805B1 (fr)	2010-10-01
MX2010004831A (es)	2010-05-21
DK2207808T3 (da)	2013-08-05
AU2008317724A1 (en)	2009-05-07
ES2425768T3 (es)	2013-10-17
CY1114345T1 (el)	2016-08-31
AR072934A1 (es)	2010-09-29
CN101910200B (zh)	2013-12-18
CL2008003240A1 (es)	2009-06-05
NZ584911A (en)	2011-08-26
CN101910200A (zh)	2010-12-08
JO2876B1 (en)	2015-03-15
HK1143597A1 (en)	2011-01-07
EP2207808B1 (fr)	2013-05-08
PL2207808T3 (pl)	2013-11-29
CO6270357A2 (es)	2011-04-20
BRPI0818928B1 (pt)	2021-12-07
TW200934791A (en)	2009-08-16
RU2010122044A (ru)	2011-12-10
ZA201002799B (en)	2011-01-26
KR101574814B1 (ko)	2015-12-04
CA2704357A1 (fr)	2009-05-07
US20120171215A1 (en)	2012-07-05
RU2513697C2 (ru)	2014-04-20
TWI429656B (zh)	2014-03-11
WO2009056509A1 (fr)	2009-05-07
US8163285B2 (en)	2012-04-24
SI2207808T1 (sl)	2013-09-30
US20110027284A1 (en)	2011-02-03
AU2008317724B2 (en)	2011-06-02
MY149546A (en)	2013-09-13
US8758754B2 (en)	2014-06-24
IL221723A (en)	2014-08-31

Publication	Publication Date	Title
TN2009000190A1 (en)	2010-10-18	Lingo binding molecules and pharmaceutical use thereof
PH12014501091A1 (en)	2014-07-28	Binding molecules for bcma and cd3
MY177065A (en)	2020-09-03	4-1bb binding molecules
TN2010000199A1 (en)	2011-11-11	Improved nogo-a binding molecules and pharmaceutical use thereof
PH12015501672A1 (en)	2015-10-12	Binding molecules for bcma and cd3
UA100682C2 (ru)	2013-01-25	АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
PH12015500806A1 (en)	2015-12-02	Binding molecules to the human ox40 receptor
GB201020995D0 (en)	2011-01-26	Biological materials and uses thereof
MX2009005189A (es)	2009-06-30	Anticuerpos humanos monoclonales para btla y metodos de uso.
TW201129379A (en)	2011-09-01	Anti-Orai1 antigen binding proteins and uses thereof
MX2012011405A (es)	2013-01-29	Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas.
MX2009012950A (es)	2010-03-26	ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2014001916A (es)	2014-05-01	Moleculas biespecificas de union a antigeno.
MY150246A (en)	2013-12-31	Alpha 5 - beta 1 antibodies and their uses
MX2011009220A (es)	2011-09-28	Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
JO2991B1 (ar)	2016-09-05	بروتينات رابطة لمولد ضد المستقبل ايه للانترليوكين 17
SG146660A1 (en)	2008-10-30	Nogo-a binding molecules and pharmaceutical uses thereof
WO2009106532A3 (fr)	2009-12-17	Utilisation de protéines contenant un domaine tir procaryotique comme agents thérapeutiques et diagnostiques
TH71697A (th)	2005-11-03	โมเลกุลสำหรับจับ nogo-a และการใช้สารเหล่านี้ในทางยา
TN2011000150A1 (en)	2012-09-05	Anti cxcr4 antibodies and their use for the treatment of cancer
UA97414C2 (ru)	2012-02-10	Выделенное человеческое антитело, связывающееся с gm-csf